5,611 Shares in Biogen Inc. $BIIB Purchased by Caprock Group LLC

Caprock Group LLC purchased a new stake in Biogen Inc. (NASDAQ:BIIB) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 5,611 shares of the biotechnology company’s stock, valued at approximately $742,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in BIIB. Norges Bank acquired a new position in Biogen during the second quarter worth $284,358,000. Orion Porfolio Solutions LLC increased its stake in shares of Biogen by 6,828.4% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock worth $64,965,000 after purchasing an additional 509,809 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in shares of Biogen by 190.7% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 624,371 shares of the biotechnology company’s stock valued at $78,415,000 after purchasing an additional 409,591 shares during the period. AustralianSuper Pty Ltd lifted its stake in Biogen by 85.9% in the 2nd quarter. AustralianSuper Pty Ltd now owns 739,416 shares of the biotechnology company’s stock valued at $92,863,000 after purchasing an additional 341,719 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in Biogen by 1.5% during the second quarter. Vanguard Group Inc. now owns 17,290,651 shares of the biotechnology company’s stock worth $2,171,533,000 after purchasing an additional 257,812 shares during the period. Institutional investors own 87.93% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on BIIB shares. UBS Group assumed coverage on Biogen in a research report on Tuesday, January 6th. They issued a “neutral” rating and a $185.00 price objective for the company. Mizuho raised their price target on Biogen from $207.00 to $236.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. Piper Sandler upped their price objective on shares of Biogen from $157.00 to $177.00 and gave the company a “neutral” rating in a report on Monday, February 9th. Wall Street Zen cut shares of Biogen from a “buy” rating to a “hold” rating in a research note on Sunday, November 9th. Finally, Wedbush lifted their target price on shares of Biogen from $178.00 to $187.00 and gave the stock a “neutral” rating in a report on Monday, February 9th. Twelve analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $205.84.

Insider Activity

In other Biogen news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the sale, the insider owned 8,043 shares in the company, valued at $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 0.18% of the company’s stock.

Biogen Trading Up 0.5%

Shares of BIIB stock opened at $196.52 on Tuesday. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $202.41. The stock’s fifty day moving average price is $178.54 and its two-hundred day moving average price is $159.77. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. The company has a market cap of $28.84 billion, a PE ratio of 22.31, a P/E/G ratio of 1.56 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same period in the prior year, the company earned $3.44 EPS. Biogen’s revenue for the quarter was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities analysts predict that Biogen Inc. will post 15.83 EPS for the current fiscal year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.